NewcelX Ltd. - Ordinary Shares (NCEL)

Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market session. The company's market cap stands at $4.8 million. NewcelX (NASDAQ:NCEL) shares increased by 15.08% to

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial

ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company’s strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company’s development strategy.

Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program